A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Santen Pharmaceutical Co., Ltd.325 enrolled

Overview

To investigate whether the IOP lowering efficacy of STN1012600 ophthalmic solution 0.002% is non-inferior to that of latanoprost 0.005% in subjects with POAG or OHT after treatment for 4 weeks.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

325

Conditions

Primary Open Angle Glaucoma, Ocular Hypertension

Interventions

STN1012600 ophthalmic solution 0.002%DRUG

1 drop STN1012600 ophthalmic solution 0.002% once daily for 3 months

Latanoprost ophthalmic solution 0.005%DRUG

1 drop Latanoprost ophthalmic solution 0.005% once daily for 3 months

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18 years of age or older. * Diagnosis of POAG or OHT in both eyes, or one eye with POAG and the other with OHT. * Corrected Visual Acuity of +0.60 logMAR (Decimal visual acuity 0.3) or better in each eye. Exclusion Criteria: * Presence of any active severe external ocular disease, inflammation, or infection of the eye and/or eyelids in either eye. * History of severe ocular trauma in either eye. * Any condition that prevents clear visualization of the fundus in either eye. * Known allergy, hypersensitivity or contraindications to any components of the study medications or other study related procedures/medications. * History of ocular surgery specifically intended to lower IOP in either eye. * History of keratorefractive surgery in either eye. * Females who are pregnant, nursing, or planning a pregnancy. * Subjects with known or suspected drug or alcohol abuse. * Participation in other investigational drugs or device clinical trials within 30 days prior to Screening. * Any decision by the Investigator to terminate a subject in screening or declare any subject ineligible for any sound medical reason.

Locations (44)

Outcomes

Primary Outcomes

Change from baseline in mean diurnal intraocular pressure

Change from baseline in mean diurnal intraocular pressure at Week 4

Time frame: 4 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Eyecare Nagoya

Aichi, Japan

Kitanagoya Eye Clinic

Aichi, Japan

Takahashi Eye Clinic

Aichi, Japan

Kawabata Eye Clinic

Chiba, Japan

Mitsuhashi Eye Clinic

Chiba, Japan

Shisui Ophthalmology Clinic

Chiba, Japan

Takeda Eye Clinic

Hokkaido, Japan

Kanamori Eye Clinic

Hyōgo, Japan

Dannoue Eye Clinic

Kanagawa, Japan

Hodogaya iina Eye Clinic

Kanagawa, Japan

...and 34 more locations